-
1
-
-
0034671387
-
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
-
Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60(24): 6921-6926, 2000.
-
(2000)
Cancer Res
, vol.60
, Issue.24
, pp. 6921-6926
-
-
Ando, Y.1
Saka, H.2
Ando, M.3
-
2
-
-
34250202527
-
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1*6 and *28
-
Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17(7): 497-504, 2007.
-
(2007)
Pharmacogenet Genomics
, vol.17
, Issue.7
, pp. 497-504
-
-
Minami, H.1
Sai, K.2
Saeki, M.3
-
3
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
DOI 10.1200/JCO.2004.05.113
-
Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2): 229-237, 2004. (Pubitemid 41095086)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.2
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
4
-
-
0036843113
-
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction
-
DOI 10.1200/JCO.2002.03.123
-
Raymond E, Boige V, Faivre S, et al: Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 20(21): 4303-4312, 2002. (Pubitemid 35266290)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.21
, pp. 4303-4312
-
-
Raymond, E.1
Boige, V.2
Faivre, S.3
Sanderink, G.-J.4
Rixe, O.5
Vernillet, L.6
Jacques, C.7
Gatineau, M.8
Ducreux, M.9
Armand, J.-P.10
-
5
-
-
2342584118
-
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer
-
DOI 10.1200/JCO.2004.10.043
-
Meyerhardt JA, Kwok A, Ratain MJ, et al: Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 22(8): 1439-1446, 2004. (Pubitemid 41103626)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.8
, pp. 1439-1446
-
-
Meyerhardt, J.A.1
Kwok, A.2
Ratain, M.J.3
McGovren, J.P.4
Fuchs, C.S.5
-
6
-
-
34548598459
-
UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
-
DOI 10.1093/jnci/djm115
-
Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99(17): 1290-1295, 2007. (Pubitemid 47394168)
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.17
, pp. 1290-1295
-
-
Hoskins, J.M.1
Goldberg, R.M.2
Qu, P.3
Ibrahim, J.G.4
McLeod, H.L.5
|